ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Results of Operations and Financial Condition

Item2.02

On March 1, 2017, we issued a press released titled Zosano Pharma
Reports Fourth Quarter and Fiscal 2016 Financial Results and
Business Update. The press release is furnished herewith as
Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference into this Item 2.02.

The information in Item 2.02 of this Form 8-K (including Exhibit
99.1) shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly
set forth by specific reference in such filing.

(d)Exhibits.

2

About ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN)

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Recent Trading Information

ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) closed its last trading session up +0.18 at 2.68 with 2,205,823 shares trading hands.